0
Social Media Considerations in Pharmacovigilance<br />Sandeep Bhat, MSE<br />
Disclaimer<br />The following slides represent my thoughts, opinions, personal musings, attempts at using abstractions and...
Preview<br /><ul><li>Definition(s)
Types
Disparities/Commonalities
How “we” think
Technology, Media
Influencers, Getting “Buy In”
Things to consider (things to think about)
News, Implementation, Research</li></li></ul><li>DefinitionsSocial Media Definition via Google<br /><ul><li> media designe...
Types<br /><ul><li>Blog
Wiki
Twitter
Social Media Platforms</li></li></ul><li>Types<br /><ul><li>Blog
www.doseofdigital.com
Wikipedia
www.wikipedia.org
Twitter
www.twitter.com
Platform Environments
Facebook, LinkedIn/Xing</li></li></ul><li>DisparitiesCharacteristics<br />Social Media<br />Unstructured data<br />Unstruc...
CommonalitiesCharacteristics<br />Social Media<br />Hot topic: A “Trend”<br />Highly Visible in public<br />Everyone has a...
How Technology Professionalslook at it <br />
Data Deluge Semantic Enablement<br />SAP<br />Legacy<br />REFDB<br />GSM<br />NCBI<br />Manual Curation<br />
Data DelugeMining Algorithms<br />
Data DelugeMetadata Management<br />
How Media Professionals look at it <br />
Social Media – Areas of Influence<br />
Social Media –Influence Channels<br />
Gaining Support/Buy-In<br />Shepherds/Stewards:<br /><ul><li> Financial Support
 Business Direction
 Executive Visibility
 Management</li></ul>Stewards:<br />Qualified Person PV<br />Medical Affairs<br />Regulatory Affairs<br />Leaders/Connecto...
 Ensure Visibility </li></ul>Controllers/Operators:<br /><ul><li> Operationally
 Technologically
 Governance</li></ul>Controllers:<br />Leaders:<br />Information Management<br />Quality and Compliance<br />Legal<br />Co...
People, Process, Tools<br />How<br />Why <br />Who<br />What<br />
Things to Think About<br />
Earlier this year…<br />(News about this)<br />Should pharma harness social media for R&D?<br />January 24, 2011 — 11:09am...
Upcoming SlideShare
Loading in...5
×

Social Media Considerations In Pharmacovigilance Visiongain 20110317 (Sandeep Bhat)

1,606

Published on

Presented at the 6th Annual Pharmacovigilance Conference 2011 (London March 17th)

Published in: Technology, Business
0 Comments
0 Likes
Statistics
Notes
  • Be the first to comment

  • Be the first to like this

No Downloads
Views
Total Views
1,606
On Slideshare
0
From Embeds
0
Number of Embeds
1
Actions
Shares
0
Downloads
17
Comments
0
Likes
0
Embeds 0
No embeds

No notes for slide
  • Heat map profiling of spontaneously reported adverse events for a single drug. This heat map is divided into different spaces according to MedDRA (the Medical Dictionary for Regulatory Activities) terms; the rectangles outlined in white and labeled are the system–organ classes. The smaller squares represent the 10,000 or so MedDRA preferred terms that are grouped with respect to the hierarchy of MedDRA. The heat map is interactive, and as a computer cursor is moved over these squares, information appears concerning where that square falls in the MedDRA grouping.SOURCE: DuMouchel, 2007.From: 8, PharmacovigilanceEmerging Safety Science: Workshop Summary.Institute of Medicine (US) Forum on Drug Discovery, Development, and Translation.Washington (DC): National Academies Press (US); 2008.Copyright © 2008, National Academy of Sciences.NCBI Bookshelf. A service of the National Library of Medicine, National Institutes of Health.
  • Transcript of "Social Media Considerations In Pharmacovigilance Visiongain 20110317 (Sandeep Bhat)"

    1. 1. Social Media Considerations in Pharmacovigilance<br />Sandeep Bhat, MSE<br />
    2. 2. Disclaimer<br />The following slides represent my thoughts, opinions, personal musings, attempts at using abstractions and creativity. They are are in no way representative of my employer MphasiS Ltd., or the company that represents its majority ownership (Hewlett-Packard Corp.) <br />
    3. 3. Preview<br /><ul><li>Definition(s)
    4. 4. Types
    5. 5. Disparities/Commonalities
    6. 6. How “we” think
    7. 7. Technology, Media
    8. 8. Influencers, Getting “Buy In”
    9. 9. Things to consider (things to think about)
    10. 10. News, Implementation, Research</li></li></ul><li>DefinitionsSocial Media Definition via Google<br /><ul><li> media designed to be disseminated through social interaction, created using highly accessible and scalable publishing techniques. …</li></ul>en.wikipedia.org/wiki/Social_media<br /><ul><li>media that is created to be shared freely</li></ul>en.wikipedia.org/wiki/social_media<br /><ul><li>user-created video, audio, text or multimedia that are published and shared in a social environment, such as a blog, wiki or video hosting site. </li></ul>www.capilanou.ca/help/login-page/active-cms/glossary.html <br /><ul><li>website or web service that utilizes a 'social' or 'Web 2.0' philosophy. This includes blogs, social networks, social news, wikis, et </li></ul>webtrends.about.com/od/web20/a/web20-glossary_2.htm <br /><ul><li>any form of online publication or presence that allows end users to engage in multi-directional conversations in or around the content on the website </li></ul>www.onlinematters.com/glossary.htm <br /><ul><li>the use of technology combined with social interaction to create or co-create value </li></ul>www.no2pen.com/blog/2010/01/social-media-dictionary-for-small-businesses/ <br />
    11. 11. Types<br /><ul><li>Blog
    12. 12. Wiki
    13. 13. Twitter
    14. 14. Social Media Platforms</li></li></ul><li>Types<br /><ul><li>Blog
    15. 15. www.doseofdigital.com
    16. 16. Wikipedia
    17. 17. www.wikipedia.org
    18. 18. Twitter
    19. 19. www.twitter.com
    20. 20. Platform Environments
    21. 21. Facebook, LinkedIn/Xing</li></li></ul><li>DisparitiesCharacteristics<br />Social Media<br />Unstructured data<br />Unstructured process<br />Unregulated<br />Uncontrolled<br />Ungoverned<br />“Not” Quality Driven<br />Disruptive<br />Non-specific orientation<br />Business Area <br />Pharmacovigilance<br />Structured data<br />Structured process<br />Highly regulated<br />Controlled<br />Governed<br />Quality Driven<br />Purposefully nondisruptive<br />Highly specific orientation<br />Business Area<br />
    22. 22. CommonalitiesCharacteristics<br />Social Media<br />Hot topic: A “Trend”<br />Highly Visible in public<br />Everyone has an understanding of the benefit<br />Everyone has an understanding of the harm <br />Rapid – almost real time!<br />Global Phenomena<br />Source is always from the field<br />Pharmacovigilance<br />Sensitive topic<br />Can be Highly visible to public<br />Everyone can easily understand the benefit<br />Everyone can easily understand the historical precept of risk/harm<br />Intention to be rapid<br />Going to be global<br />Source is from the field<br />
    23. 23. How Technology Professionalslook at it <br />
    24. 24. Data Deluge Semantic Enablement<br />SAP<br />Legacy<br />REFDB<br />GSM<br />NCBI<br />Manual Curation<br />
    25. 25. Data DelugeMining Algorithms<br />
    26. 26. Data DelugeMetadata Management<br />
    27. 27. How Media Professionals look at it <br />
    28. 28. Social Media – Areas of Influence<br />
    29. 29. Social Media –Influence Channels<br />
    30. 30. Gaining Support/Buy-In<br />Shepherds/Stewards:<br /><ul><li> Financial Support
    31. 31. Business Direction
    32. 32. Executive Visibility
    33. 33. Management</li></ul>Stewards:<br />Qualified Person PV<br />Medical Affairs<br />Regulatory Affairs<br />Leaders/Connectors:<br /><ul><li> Drive the socialization
    34. 34. Ensure Visibility </li></ul>Controllers/Operators:<br /><ul><li> Operationally
    35. 35. Technologically
    36. 36. Governance</li></ul>Controllers:<br />Leaders:<br />Information Management<br />Quality and Compliance<br />Legal<br />Corporate Communications<br />High Profiled Individuals<br />
    37. 37. People, Process, Tools<br />How<br />Why <br />Who<br />What<br />
    38. 38. Things to Think About<br />
    39. 39. Earlier this year…<br />(News about this)<br />Should pharma harness social media for R&D?<br />January 24, 2011 — 11:09am ET | By Tracy Staton<br />http://www.fiercepharma.com/story/should-pharma-harness-social-media-rd/2011-01-24#ixzz1GqT7HyK1 <br />When pharma folks talk about social networking, it's usually in a marketing or public relations context. Using Twitter to generate traffic to a disease-awareness website or to report news about a new drug; launching iPad apps to help patients manage their diabetes; monitoring blog comments for accuracy and responding with the facts.<br />But a Boston Globe op-ed suggests that social media could be a new frontier for drug development. If pharma companies could gather real-world data from prescribers, they might find new uses for existing drugs. As the authors point out, Viagra resulted from side-effect reports in a cardiovascular trial, and some psychotropic meds trace back to a tuberculosis study. Through physician postings online, drugmakers might identify other unintended benefits of their meds.<br />
    40. 40. Earlier this year…<br />(News about this… cont’d)<br />So why doesn't Big Pharma set something up? It could be a thorny FDA problem, given the ban on off-label promotion. But a greater fear might be its unintended consequences. Set up a networking site to find unanticipated benefits, and you might come up with unexpected safety problems instead. Very public safety problems, given that the reports would be online and out in the open. And such unverified safety problems could spook patients .<br />Such is the double-edged sword of social media--it's a means of spreading both good and bad news. And like everything else online, it can't be tightly controlled.<br />FiercePharma article posted on Jan 24, 2011 http://www.fiercepharma.com/story/should-pharma-harness-social-media-rd/2011-01-24#ixzz1GqT7HyK1 <br />
    41. 41. Lots of Information?<br />Deluge of new information<br />Uncontrolled context<br />Unknown source<br />
    42. 42. What you already do<br />Active Surveillance Systems<br />Expected, planned, monitored<br />Spontaneous (unsolicited) event<br />Unscheduled, Unknown <br />
    43. 43. Truth?<br />The question of accuracy?<br />The question of truth?<br />Source Data Verification<br />Qualified and Educated Source<br />
    44. 44. Temporally, when do you record<br />A blog can list multiple parts of the same event<br />Start, in the middle, at the end?<br />How to you code a “Conversation”?<br />
    45. 45. Feedback to the public<br />Can Social Media be reasoning we can use to promote “good” communication (and eventual reporting) of safety concerns – back to the public audience?<br />We seek to obtain at the onset 4 relevant fields<br />Via the right outlets/channels, message are:<br />VERY IMPACTFUL<br />VERY RAPID<br />
    46. 46. Last Week<br />(News about this)<br />Looking for Guidance, Pharma Left Waiting<br />Industry Would Prefer Some Sort of Rulemaking for Social Media, but FDA Delays<br />March 07, 2011 – By: Rich Thomaselli<br />http://adage.com/article/news/drug-makers-wait-fda-ruling-social-media-dtc-ads/149214/<br /> <br />The biggest regulatory issue involving the pharmaceutical and health-care industries is actually a lack thereof.<br />The Food and Drug Administration has continually delayed the announcement of new advertising guidelines for online and social-media marketing -- despite holding public hearings on the topic more than 15 months ago -- leaving drug makers and health-care agencies alike in no-man's land with a lack of clearly defined principles for internet advertising.<br />
    47. 47. Last Week<br />(News about this … cont’d)<br />Now, after anticipating changes that were hoped to be as broad as the landmark 1997 FDA guidelines regarding direct-to-consumer broadcast advertising of prescription drugs, the industry is preparing for little movement from the status quo when it comes to social media.<br />Twice in February 2011, Tom Abrams, the head of FDA's Division of Drug Marketing, Advertising and Communications, suggested that little will change. On Feb. 8, speaking at the ePharma Summit in New York, Mr. Abrams conceded that the process is "taking longer than we thought," but added, "We owe it to you to get this right," according to Medical Marketing & Media.<br />But part of the delay, he said, was concern on the part of FDA that social-media platforms such as Twitter and Facebook would not be around in the future. "We did not want the guidances to become quickly outdated," Mr. Abrams said.<br />
    48. 48. Last Week<br />(News about this … cont’d 2)<br />On Feb. 22, speaking at the Drug Information Association's annual marketing meeting in Washington, D.C., Mr. Abrams said, "There will be guidance on some specific matters, but there will be no new regulations or new standards. Look at our recent Warning Letters involving social media, such as Facebook. These Warning Letters cite existing rules and do not make new policy.“<br />"We took it as Tom Abrams saying there's going to be some social-media guidance but it's not going to change the rules," John Kamp, director of the Coalition for Healthcare Communication, told Advertising Age. "This is going to be a pretty serious disappointment to pharma companies hoping there would be some kind of change in DDMAC's attitude."<br />"The problem," said one health-care ad-agency president, who asked not to be identified, "is that the digital space is so vastly different from traditional 30-second spot advertising that the [current] guidelines don't apply online. There needs to be significant change, and it doesn't appear there's going to be."<br />
    49. 49. A reason for better communication?<br />Can Social Media be used to promote good communication (and eventual reporting) of patient safety – back to the public audience?<br />Professionals obtaining the relevant 4 fields<br />Via the right outlets/channels, message are:<br />VERY IMPACTFUL<br />VERY RAPID<br />
    50. 50. Impact<br />Social Media already has impacted the community of medical practitioners<br />www.sermo.com<br />Social Media has impacted the community of patients:<br />www.patientslikeme.com<br />Social Media has impacted the community of medical education<br />Social Media has impacted the community of medical care facilities<br />Mayo Clinic<br />
    51. 51. Scope<br />This is a massive movement<br />Potential immediate impact<br />Large scale pandemic/epidemic/outbreak<br />Vaccine “gone wrong”<br />Use all your employees to be stewards<br />
    52. 52. “Sample” Social Media Guideline<br />Roche Social Media Principles (in short):<br />7 Rules for PROFESSIONAL online activities Speaking “on behalf of” Roche <br />Follow the Roche Group Code of Conduct and Communications Policy. <br />Follow approval processes for publications and communication. <br />Mind Copyrights and give credit to the owners. <br />Use special care if talking about Roche products or financial data. <br />Identify yourself as a representative of Roche. <br />Monitor your relevant social media channels. <br />Know and follow our Record Management Practices.<br />7 Rules for PERSONAL online activities Speaking “about” Roche <br />Be conscious about mixing your personal and business lives. <br />You are responsible for your actions. <br />Follow the Roche Group Code of Conduct. <br />Mind the global audience. <br />Be careful if talking about Roche. Only share publicly available information. <br />Be transparent about your affiliation with Roche and that opinions raised are your own. <br />Be a “scout” for sentiment and critical issues. <br />
    53. 53. “Sample” Social Media Guideline<br />
    54. 54. “Sample” Social Media Guideline<br />
    55. 55. Academic Article<br />Linguistics and Text Mining<br />
    56. 56. Academic Article<br />Linguistics and Text Mining<br />
    57. 57. IOMPresentation<br />
    58. 58. Review<br /><ul><li>Definition(s)
    59. 59. Types
    60. 60. Disparities/Commonalities
    61. 61. How “we” think
    62. 62. Technology, Media
    63. 63. Influencers, Getting “Buy In”
    64. 64. Things to consider (things to think about)
    65. 65. News, Implementation, Research</li></li></ul><li>Thank you<br />Sandeep Bhat<br />Sandeep.bhat@mphasis.com<br />http://www.linkedin.com/in/bhatsandeep<br />
    1. A particular slide catching your eye?

      Clipping is a handy way to collect important slides you want to go back to later.

    ×